MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

Neurocrine Biosciences Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

136.03 -0.68

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

136.02

Max

137.75

Pagrindiniai rodikliai

By Trading Economics

Pajamos

100M

108M

Pardavimai

115M

688M

P/E

Sektoriaus vid.

41.997

35.739

Pelno marža

15.636

Darbuotojai

1,800

EBITDA

129M

153M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+22.86% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

679M

14B

Ankstesnė atidarymo kaina

136.71

Ankstesnė uždarymo kaina

136.03

Naujienos nuotaikos

By Acuity

21%

79%

44 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Neurocrine Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-01-28 00:03; UTC

Karštos akcijos

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

2025-03-14 09:30; UTC

Svarbiausios naujienos

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Akcijų palyginimas

Kainos pokytis

Neurocrine Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

22.86% į viršų

12 mėnesių prognozė

Vidutinis 168 USD  22.86%

Aukščiausias 200 USD

Žemiausias 124 USD

Remiantis 26 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Neurocrine Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

26 ratings

23

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

109.55 / 121.61Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

44 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
help-icon Live chat